Patent ID: 8242173

Claim:
A method for treating or inhibiting the progression of a PPAR-delta mediated condition selected from the group consisting of diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, hypo-HDL-cholesterolemia, atherosclerosis, obesity, and complications thereof, said method comprising administering to a patient in need of treatment a pharmaceutically effective amount of a compound of Formula (I): wherein X is selected from a covalent bond, S, or O; Y is S or O; - - - W - - - represents a group selected from ═CH—, —CH═, —CH 2 —, —CH 2 —CH 2 —, ═CH—CH 2 —, —CH 2 —CH═, ═CH—CH═, and —CH═CH—; Z is selected from O, CH, and CH 2 , provided when Y is O, Z is O; R 1 and R 2 are independently selected from H, C 1-3 alkyl, C 1-3 alkoxy, halo, and NR a R b wherein R a and R b are independently H or C 1-3 alkyl; R 3 and R 4 are independently selected from H, halo, cyano, hydroxy, acetyl, C 1-5 alkyl, C 1-4 alkoxy, and NR c R d wherein R c and R d are independently H or C 1-3 alkyl, provided that R 3 and R 4 are not both H; R 5 and R 6 are independently selected from H, C 1-8 alkyl and substituted C 1-8 alkyl, provided that R 5 and R 6 are not both H; R 7 is selected from halo, phenyl, phenoxy, (phenyl)C 1-5 alkoxy, (phenyl)C 1-5 alkyl, C 2-5 heteroaryloxy, C 2-5 heteroarylC 1-5 alkoxy, C 2-5 heterocyclyloxy, C 1-9 alkyl, C 1-8 alkoxy, C 2-9 alkenyl, C 2-9 alkenyloxy, C 2-9 alkynyl, C 2-9 alkynyloxy, C 3-7 cycloalkyl, C 3-7 cycloalkoxy, C 3-7 cycloalkyl-C 1-7 alkyl, C 3-7 cycloalkyl-C 1-7 alkoxy, C 3-7 cycloalkyloxy-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 1-5 alkoxy-X 1-5 alkoxy, or C 3-7 cycloalkyloxy-C 1-7 alkoxy; R 8 is H when - - - W - - - represents a group selected from —CH═, —CH 2 —, —CH 2 —CH 2 —, —CH 2 —CH═, and —CH═CH—, or R 8 is absent when - - - W - - - represents a group selected from ═CH—, ═CH—CH 2 —, and ═CH—CH═; and n is 1 or 2; or a pharmaceutically acceptable salt thereof.